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Abstract 
AIM: This work investigated associations between tissue inhibitor metalloproteinase-1 and diabetic cardiovascular 
diseases in type 2 diabetic patients; also it investigated the role of osteopontin in the diagnosis of type 2 
cardiovascular diabetes complications. 
SUBJECTS AND METHODS: These were examined on eighty subjects, divided into three groups as follows: 
twenty volunteer healthy control subjects, thirty type 2 diabetes mellitus (DM) patients, and thirty cardiovascular, 
diabetic patients. Full clinical measurements were carried out, and the expression level of tissue inhibitor 
metalloproteinase-1 in blood samples was analysed by real-time PCR, using gene-specific primer pairs. Also 
osteopontin concentrations had been measured by the enzyme-linked immunosorbent assay. Data were tested 
statistically by parametric tests. 
RESULTS: The concentrations of osteopontin and the expression levels of tissue inhibitor metalloproteinase-1 
were significantly increased in diabetic and cardiovascular diabetic groups compared to control group also they 
were significantly increased in the cardiovascular diabetic group compared to the diabetic group. 
CONCLUSION: Tissue inhibitor metalloproteinase-1 and osteopontin concentrations were significantly increased 
in diabetic patients with cardiovascular complications than other groups. 
 
 
 
 
Introduction 
 
The expanding commonness of type 2 
diabetes mellitus (T2DM) calls for creating 
corresponding screening systems for early 
recognisable proof of high-risk people for the disease 
or its complexities [1]. The condition is comorbid with 
macrovascular disorders, for example, coronary artery 
disease, peripheral arterial disease, and stroke. 
Diabetes mellitus is a major risk cause for 
cardiovascular disease (CVD) which is the main cause 
of death among the diabetic patients. Diabetes mellitus 
intensifies atherosclerosis and heart failure 
mechanisms. Regrettably, these mechanisms are not 
sufficiently modulated by therapeutic strategies 
focusing only on the glycemic control with currently 
available drugs or approaches [2], underscoring the 
requirement for forceful CVD risk factor management.  
The diagnosis and screening of diabetes 
mellitus have been changed since the earlier scientific 
statement, with the incorporation of glycated 
haemoglobin (HbA1c) in the diagnostic gauges of type 
II diabetes of at least 6.5% [3]. Specifically, HbA1c was 
used as a preferable standardised assay over glucose, 
a better indicator for overall glycemic exposure, and as 
less subject to pre-analytic instability, prandial status, 
biological variability, and intense stress [4].  
While insulin and glucose are the most 
entrenched biomarkers, progresses in the “omics” 
technologies have recognised the extent of molecules 
including genetic variants, small metabolites, RNA 
transcripts, and proteins that could serve as indicators 
of diabetes risk [5].  
Circulating markers of extracellular matrix 
turnover, such as matrix metalloproteinases (MMP) and 
their tissue inhibitors (TIMP), are essential to the 
vascular alternations of atheromatous vascular 
disease. TIMP-1 was considered as an endogenous 
MMP inhibitor that might include in the vascular matrix 
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fibrosis [6]. Also, it has a role in diastolic dysfunction 
and left ventricular hypertrophy by diminishing cardiac 
collagen type I turnover and expanding cardiac 
stiffness and mass [7].  
In diabetes, TIMP-1 and MMP-9 levels are 
significantly increased [8], also in this condition, 
peripheral and central artery stiffness is increased [9]. 
Amelioration in the metabolic control leads to 
decreasing in TIMP-1 levels, and this raises TIMP-1 
probability as a marker of vascular composition in 
diabetes mellitus [10], a potential purpose of mediation.  
Phosphoprotein osteopontin (OPN), also called 
secreted phosphoprotein 1 (SPP1), urinary stone 
protein, early T lymphocyte activation 1, and bone 
sialoprotein is found in various cell types [11]. In 
prevalent patients, a significant association was 
observed between atherosclerotic plaque development 
and plasma OPN levels, independently of conventional 
risk factors [12]. Moreover, high glucose and advanced 
glycation end product may lead to upregulation of OPN 
expression in the vascular wall of diabetic animal 
models and diabetic patients [13].  
In this study, the hypothesis that there may be 
a relationship between elevated both OPN levels and 
TIMP-1 expression levels and the presence of CVD in 
type 2 diabetic patients were tested.  
 
 
Subjects and Methods  
 
Patients’ data  
T of 80 subjects was recruited for that study 
and divided into three groups. Twenty volunteer healthy 
control subjects (G1), thirty type 2 diabetes mellitus 
(DM) patients (G2); disease duration 5 ± 3 years, and 
thirty type 2 diabetic patients with cardiovascular 
(coronary heart) diseases (G3); disease duration 3 ± 1 
years. Type II diabetic patients were those 
consecutively referred during routine medical care visits 
from an outpatient diabetes clinic (National Institute of 
Diabetes in Egypt). If patients had any known systemic 
diseases other than diabetes that can influence the 
needed results such as epidemiological diseases, 
chronic periodontitis, nephropathy, retinopathy, 
neuropathy, gallbladder, liver, and lung diseases, they 
were excluded in this study. Participation in this study is 
completely voluntary. Patients decide to participate, 
can stop participating at any time and may decide not 
to answer any specific question. Participants’ decision 
not to continue participating will not influence the nature 
of their relationship with a researcher or with a staff of 
this study either now or in the future. If a patient 
withdraws from the study, all associated data collected 
will be immediately destroyed wherever possible.  
 
 
Laboratory markers of diabetes mellitus 
Blood samples were collected from all fasting 
participants in this study, Lipemic and hemolyzed 
samples were excluded, samples were analysed for 
HbA1c by cation - exchange resin method [14]. Total 
cholesterol (TC) and triglycerides (TG) in serum were 
measured by colourimetric enzymatic method [15]. 
Also, high-density lipoprotein cholesterol (HDL 
cholesterol) was measured [16], and low-density 
lipoprotein cholesterol (LDL cholesterol) was evaluated 
by Friedewald formula [17]. Moreover, heart function 
biomarkers such as creatine phosphokinase-MB (CK-
MB), creatine phosphokinase (CK), and lactate 
dehydrogenase (LDH) were measured by enzymatic 
method [18].  
Tissue inhibitor of metalloproteinases-1 (TIMP-
1) analysis TIMP-1 expression levels were determined 
using Real Time PCR (qPCR) which performed with 
SYBR Green (5X HOT FIREPol®EvaGreen® qPCR 
Mix Plus) for tenfold diluted cDNA samples in a triplet 
set using specific primers pairs which synthesized in 
HVD Life Sciences co., Vienna, Austria; forward primer 
sequence (CTGGCTTCTGGCATCCTGTTG) and 
reverse primer sequence 
(GTCTGGTTGACTTCTGGTGTCC) (NG_012533.1, 
NM_003254.2) against glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) as a reference gene; forward 
primer sequence (CAGCCTCAAGATCATCAGCAATG) 
and reverse primer sequence 
(CAGTCTTCTGGGTGGCAGTGA) (NG_007073.2, 
Variant1: NM_002046.5, Variant 2: NM_001256799.2, 
Variant 3: NM_001289745.1, Variant 4: 
NM_001289746.1). Blood RNA was extracted by EZ-10 
column blood RNA purification kit (cat.# BS82313) 
according to the manufacturer's instructions, and it was 
eluted from the membrane in the presence of RNase - 
free water. First cDNA strand was synthesised 
immediately after RNA extraction. Reaction 
components were mixed as follows: 5 μg RNA, 0.5 μl 
(10 μmol) Oligo dT and 0.5 μl (10 μmol) random primer, 
then the volume was adjusted to 12.5 μl using diethyl 
pyrocarbonate (DEPC) treated water. The reaction 
tubes were mixed well and incubated 5 min at 60
o
C to 
remove the RNA secondary structure, then chilled on 
ice. Finally, the following components were added to 
the reaction mixture: 2 μl (10 mM) dNTPs, 4 μl (5 X) 
Moloney murine leukaemia virus (MMLV) buffer, 0.5 μl 
ribolock (40 u/μl) and 1 μl reverse transcriptase 
enzyme (MMLV-RTase) (20 u/μl). As a termination 
step, the final reaction mixture (20 μl) was spun down 
and incubated at room temperature for 10 min, then at 
42
o
C for 1hour followed by 10 min at 70
o
C. cDNA 
samples were stored at - 20
o
C for the amplification 
steps which performed on Bio-Rad CFX ManagerTM 
software, version 3.1. The qPCR was performed 
according to the following program: Initial denaturation 
and polymerase activation step for 10 min at 95°C, 
denaturation step at 95°C for 30 sec, annealing step for 
30 sec at 57°C for GAPDH and TIMP-1 and finally, the 
elongation step for 45 sec at 72°C. The denaturation, 
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the annealing and the elongation steps were performed 
at 50 cycles.  
 
Osteopontin (OPN) analysis 
Osteopontin concentrations were determined 
using commercially available enzyme-linked 
immunosorbent assay (ELISA) kit according to the 
manufacturer’s protocol (BOSTER Biological 
Technology Co., Inc., USA; cat.# EK0482). All samples 
were analysed in duplicate. Horseradish peroxidase 
was conjugated with the secondary antibody, and 
tetramethyl benzidine (TMB) was used as a substrate. 
The absorbance was measured at 450 nm. 
Osteopontin concentration was expressed as pg/ml.  
 
Statistical analysis 
SPSS 17.0 software was used to execute the 
statistical analyses, and the results were represented 
by the mean ± SD. Student's t-test was used to make a 
comparison between the groups and correlations were 
assessed by Pearson's correlation test using P < 0.05 
as considered to be significant.  
 
 
Results 
 
Clinical findings in the diabetic patients  
Fasting blood sugar (FBS), glycosylated Hb 
(HbA1c%), Lipid profile; total cholesterol (TC), 
triglyceride (TG), low density lipoprotein cholesterol 
(LDL-C), LDL-C/HDL-C ratio, cardiac biomarkers; 
creatine phosphokinase (CK), creatine phosphokinase-
MB isoenzyme (CK-MB), and lactate dehydrogenase 
(LDH) activities were significantly higher in the 
cardiovascular diabetic groups than that in the control 
and the diabetic group, while high-density lipoprotein 
cholesterol (HDL-C) concentrations were significantly 
lower in the cardiovascular, diabetic groups than that in 
the control and the diabetic group as clarified in Table 
1.  
Table 1: Some clinical data in control and different tested 
groups 
 Normal 
range 
Control 
group 
Diabetic 
Group 
Cardiovascular 
diabetic group 
FBS (mg/dl) 60-110 84.0 ± 8.9
**
 268.6 ± 94.2
**
 347.0 ± 66.9 
HbA1c (%)         < 6.5 4.9 ± 0.7
**
             9.1 ± 2.0
**
 10.3 ± 1.1 
TC (mg/dl) < 200 105.8 ± 9.1
**
 157.9 ±  28.9
**
 262.7 ± 19.8 
TG (mg/dl) 35-140 75.6 ± 8.7
**
 123 ± 22.8
**
 387.8 ± 71.9 
HDL-C (mg/dl)         >55 59.9 ± 4.6
**
 52.9 ± 6.8
**
 22.9 ± 4.7 
LDL-C (mg/dl) < 150 30.6 ± 11.0
**
 80.4 ± 30.1
**
 162.2 ± 21.6 
LDL-C/HDL-C         < 2       0.5
**
               1.6
**
     7.4 
CK (U/L) Up to 120 54.5 ± 10.2
**
 42.5 ± 7.8
**
 128.1 ± 23.7 
CK-MB (U/L) 0-24 21.9 ± 3.9
*
 18.5 ± 3.8
**
 25.2 ± 3.7 
LDH (U/L) 160-320 207.3 ± 12.5
**
    214.6 ± 23.8
**
 620.3 ± 101.9 
Mean ± SD, vs. cardiovascular diabetic group. *P ≤ 0.05; **P ≤ 0.001. 
 
TIMP-1 expression findings in the diabetic 
patients  
The resulted data of the normalized expression 
ratio of TIMP-1 to GAPDH as a reference gene was 
represented in Table 2, and Fig. 1, A. Also individuals' 
data were statistically analyzed from the point of view 
as ± S.D and S.E. Then the t-value results were 
checked on student's t-test to detect the significance 
level (p-value).  
Table 2: Statistical analysis of TIMP-1 expression levels and 
osteopontin concentrations in control and different tested 
groups 
  
Control 
group 
Diabetic group 
Cardiovascular 
diabetic group 
S
ta
ti
s
ti
c
a
l 
a
n
a
ly
s
is
 o
f 
 
T
IM
P
-1
 
Avg. dCT 7.03 2.27 1.39 
ddCT 0.0 -4.77 -5.65 
FC than control group 1.0 27.20 50.07 
FC than cardiovascular 
diabetic group 
0.12 0.54 1.0 
±S.D 0.75 0.9 0.72 
S.E 0.17 0.16 0.13 
F-value (ANOVA) 327.0 
T-value 
G1 - 20.3
**
 26.4
**
 
G2 - - 4.2
**
 
S
ta
ti
s
ti
c
a
l 
a
n
a
ly
s
is
 o
f 
 o
s
te
o
p
o
n
ti
n
 
OPN conc. range 6000-8500 9000-14700 9550-22000 
OPN conc. mean 7140 10765 14421 
±S.D 619.8 1588.3 3411.6 
S.E 138.6 290.0 622.9 
F-value 
ANOVA 
59.6 
T-value 
G1 - 9.7
**
 9.4
**
 
G2 - - 5.3
**
 
**
P ≤ 0.001. 
 
The present study showed that; the expression 
level of TIMP-1 gene significantly increased by 27.2 
and 50.07 folds to reference gene; GAPDH, in diabetic 
and cardiovascular diabetic patients respectively than 
normal volunteers, so it might be considered as 
diagnostic marker for DM, and its expression level 
significantly increased by 1.84 folds in cardiovascular, 
diabetic patients than the diabetic patients, so it might 
be considered as diagnostic marker for detection of 
cardiovascular complications in type 2 diabetes.  
 
Osteopontin (OPN) concentration findings 
in the diabetic patients 
The individuals’ data of osteopontin (OPN) 
concentration of different tested groups was statistically 
analysed in Table 2 and evaluated from the point of 
view as ± S.D and S.E. The result of the t-value is then 
checked on student’s t-test to find out the significance 
level (p-value).  
From the table, it appeared that highly 
significant difference (p ≤ 0.001) was found in diabetic 
group (G2) (10765 ± 1588.3 pg/ml), and 
cardiovascular, diabetic group (G3) (14421 ± 3411.6 
pg/ml) as compared with the control group (G1) (7140 ± 
619.8 pg/ml), also highly significant difference was 
appeared in G3 as compared with G2 (Fig. 1, B). 
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Figure 1: (A) TIMP-1 relative expression level (FC ± S.D). (B) 
Osteopontin concentrations (Mean ± S.D) in control and different 
tested groups. **Highly significant different with the control group G1 
(p ≤ 0.001), # Highly significant different with cardiovascular, diabetic 
group G4 
 
Table 3 showed highly significant positive 
correlation observed between osteopontin with some 
variables; FBS, HbA1c, cholesterol, triglyceride, LDL-C, 
CK, and LDH, and between TIMP-1 and HDL-C, while 
there was low significant positive correlation between 
osteopontin and CK-MB concentrations.   
 
Figure 2: Correlation between osteopontin concentrations and TIMP-1 
with some variable 
 
Also there was highly significant negative 
correlation between osteopontin and HDL-C, also 
between TIMP-1 and some variables; FBS, HbA1c, 
cholesterol, triglyceride, LDL-C, CK, and LDH, while 
there was no correlation between TIMP-1 and CK-MB 
concentrations. (Fig. 2, A-L).  
Table 3: Correlation between osteopontin concentrations and 
TIMP-1 with other variables 
Osteopontin TIMP- 1 
Variable Pearson Correlation (r) Sig. (2-tailed) Pearson Correlation 
(r) 
Sig. (2-tailed) 
FBS 0.605 H.S
**
 -0.740 H.S
**
 
HbA1c 0.656 H.S
**
 -0.777 H.S
**
 
Cholesterol 0.736 H.S
**
 -0.735 H.S
**
 
Triglyceride 0.709 H.S
**
 -0.640 H.S
**
 
HDL – cholesterol - 0.666 H.S
**
 0.663 H.S
**
 
LDL- cholesterol 0.701 H.S
**
 -0.734 H.S
**
 
CK 0.644 H.S
**
 -0.407 H.S
**
 
CK-MB 0.257 L.S
*
 -0.074 N.S 
LDH 0.618 H.S
**
 -0.549 H.S
**
 
N.S. P > 0.05; *P ≤ 0.05; **P ≤ 0.001. 
 
 
 
Discussion 
 
Diabetes mellitus is a complex disease 
affecting nearly all tissues and organs, with 158 
metabolic ramifications extending far beyond impaired 
glucose metabolism. Biomarkers may reflect the 
presence and/or severity of hyperglycemia and the 
vascular complications of diabetes [19]. 
TIMP-1 is a diagnostic marker for diabetes, in 
this study, the expression level of TIMP-1 was 
significantly increased in diabetic and cardiovascular 
diabetic patients than normal volunteers, also 
increased significantly in cardiovascular, diabetic 
patients than other diabetic groups, higher levels of 
circulating TIMP-1 was connected with the higher risk 
of diabetes and cardiovascular demise. This finding 
was consistent with Usmanova [20], furthermore, Lee 
and his colleagues who found that plasma TIMP-1 
concentration was significantly raised in type II diabetic 
patients [21]. Also in this study, the TIMP-1 expression 
level was significantly higher in diabetic patients with 
cardiovascular diseases (CVD) than in those without 
cardiovascular diseases, these were in agreement with 
Papazafiropoulou and Tentolouris results [22]. TIMP-1 
is an endogenous MMP inhibitor that might be involved 
in vascular matrix fibrosis [6] and has a role in left 
ventricular hypertrophy and diastolic dysfunction by 
reducing cardiac collagen type I turnover, thereby 
increasing cardiac mass and stiffness [6][23]. Increased 
Central and peripheral artery stiffness [9] occurs with 
diabetes [24], and higher TIMP-1 circulating levels 
complete the hypothesis that altered TIMP-1 activities 
can be related to arterial stiffness.  
Another biomarker studied in that work, was 
osteopontin (OPN) which is a phosphoprotein found in 
different types of cells [11]. In this study, Levels of 
serum OPN increased in all diabetic groups 
significantly in comparing with the control group, the 
expression of OPN was highly induced by glucose [25], 
this agreed with Takemoto and his colleagues [26] who 
reported an increase of serum OPN in diabetic patients, 
suggesting that it may be involved in the accelerated 
atherosclerosis-related to diabetes. Also in this study, 
its concentration increased in a cardiovascular, diabetic 
group significantly in comparing with the diabetic group. 
OPN is a pleiotropic cytokine that is a common and 
relevant component of many acute and chronic 
vascular or endothelial responses to injury 
characterised by inflammation and/or fibrosis, including 
atherosclerosis, arterial neointimal hyperplasia, and 
aortic stenosis [27], as well as the vascular damage, 
accompanied diabetes [28]. OPN has been acting as 
the main factor in the atherosclerosis development [29][ 
30]. Plasma OPN concentration is elevated in the 
essential hypertension, coronary artery disease (CAD), 
and restenosis [31][32][33]. In the cardiovascular 
system, OPN is one of the main regulators of the 
vascular disease and the chronic inflammation [34]. In 
other aspects of vascular diseases, Yan and his 
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colleagues [35] found that plasma OPN level, parallels 
with the severity of nephropathy and CAD in diabetes, 
suggesting that an elevated plasma OPN level can be 
used as indicator for the diabetic vasculopathy 
screening.  
This study revealed that, the expression levels 
of TIMP-1 and osteopontin concentrations had highly 
significant differences between diabetic and 
cardiovascular diabetic patients in Egypt which 
appeared in Table 2, so they could be used as 
molecular biomarkers in the diagnosis of cardiovascular 
complications in type 2 diabetic patients to predict 
potential progression and aid in case management.  
In the future, we can be hopeful that new 
blood-based biomarkers will facilitate the discovery, 
prohibition, and treatment of diabetes and its 
complications much sooner than overt disease 
develops.  
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